A notable exception is the ADC Brentuximab-vedotin (BV) that is directed against the surface protein CD30, which is particularly abundant in anaplastic large cell lymphoma (ALCL) and only rarely expressed on normal T-cells. The gene discussed is TNFRSF8; the disease is anaplastic large cell lymphoma.